Metabolism of salicylate during chronic aspirin therapy.
1. The effects of chronic administration of aspirin in therapeutic doses (3.9 g/day) on plasma and salivary salicylate levels were studied in eight subjects. 2. The urinary excretion profile for free salicylic acid and metabolites of salicylate were examined. 3. Plasma and salivary salicylate levels declined significantly after peak levels were achieved between days 3 and 10. 4. The decline in plasma and salivary salicylate levels may be due to an induction of a metabolic pathway such as salicylurate formation (Furst, Gupta & Paulus, 1977). Only the mean fraction of salicylate excreted as salicylurate appears to increase with time during the present study, although the change was not significant statistically. 5. The decline in plasma and salivary salicylate levels during chronic therapy may lead to an apparent 'tolerance' of some rheumatoid patients to aspirin.
D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D001241:Aspirin / Q000378:metabolism* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008297:Male; D012459:Salicylates / Q000097:blood / Q000378:metabolism* / Q000652:urine; D012463:Saliva / Q000378:metabolism; D013997:Time Factors
D012459:Salicylates; D001241:Aspirin